利用18F正子造影掃描在非小型細胞肺癌的再分期應用是相當助益的，但並未得到廣泛的評價。本研究共收集156位病患，回朔來評估非小型細胞肺癌的分期，依照美國癌症聯合委員會（American Joint Committee on Cancer ，AJCC）的肺癌分期，第I期和第II期通常決定了切除肺癌病灶局部界線邊緣，第IIIA期切除比局部更大的範圍，第IIIB期則主張不用手術切除，第IV期絕對不能用手術切除。比較病人最初胸部電腦斷層的發現，並正確分期出葡萄糖正子造影掃描結果，其中非小型細胞肺癌: down-staged病患佔45/156（29%），up-staged病患佔52/156（33%）。並發現出有37/156（23%）的病患為原先診斷時分期需手術，但做完正子斷層掃描調整為不需手術，而有22/156（14%）的病患原先分類為不需手術治療，做完正子斷層掃描調整為需手術治療。我們的結果證實全身葡萄糖正子斷層掃描是有利於非小型細胞肺癌之再分期，有別於傳統肺癌分期，並使之病人因此改變治療方式達60%。
The helpful of 18F-2-deoxyglucose positron emission tomography (FDG-PET) in restaging non-small cell lung cancer (NSCLC) has not been extensively evaluated. A total of 156 patients referred for restaging of NSCLC were retrospectively evaluated. According to the calssification of American Joint Committee on Cancer, stage I and stage II were definted as conventionally resectable, stage IIIA as locally advanced but resectable, stage IIIB as locally advanced but unresectable, and stage IV as absolutely unresectable. Compare to initial staging by chest computed tomographic findings,
FDG-PET down-staged 45/156 (29%) and up-staged 52/156 (33%)NSCLCs. In addition, 37/156 (23%) patients were reclassified from resectable to unresectable and 22/156 (14%) patients were reclassified from unresectable to resectable. Our results prove the helpful thehelpfulness of whole body FDG-PET for restaging NSCLC.
